Stock Evaluator: Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical, Inc. LFCR

$4.42 0.06 1.38%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 78,460
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Commentary & Analysis


Financial Summary

Share Statistics LFCR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $165.8 $1,790.4 26%
Shares Out (Mil) 37.5 94.8 42%
Institutional Ownership 90.0% 90.0% 58%
Float (Mil) 19.4 69.9 29%
Beta 1.06 1.20 63%
Avg Daily Volume (000s) 137 814 39%
Price Change
(52-week)
(37.8%) 80.2% 20%
Growth LFCR Industry
Median
Percentile
(All Stocks)
Sales (5yr) 5.1% 7.8% 37%
Net Income (5yr) 11.0% (13.7%) 57%
EPS (5yr) 13.3% 0.7% 52
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 76.2% (15.0%) 97%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na 2
Current EPS na na ($0.890)
Month Ago EPS na na ($0.810)
# Rev Up na na 0
# Rev Down na na 0
Three Months Ago EPS na na ($0.860)
Year/Year Chg na na na
Financials LFCR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $130 $785 29%
Net Income (TTM) (Mil) ($31) ($14) 20%
EPS (TTM) ($0.923) ($0.200) 22%
Operating Cash Flow (TTM) (Mil) $13 $53 39%
Net Cash Flow (TTM) (Mil) $1 ($4) 46%
Long-Term Debt (Q1) (Mil) $149 $270 47%
Enterprise Value (Q1) (Mil) $361 $2,444 31%
Valuation LFCR Industry
Median
Percentile
(All Stocks)
P/B na 2.92 na
P/E na 43.7 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 5.3 na
Ratios LFCR Industry
Median
Percentile
(All Stocks)
Gross Margin 31.4% 47.6% 37%
Net Margin (23.8%) (2.9%) 16%
ROA (12.8%) (2.8%) 24%
ROE 474.1% (4.5%) 99%
Liabilities to Assets 90.8% 43.0% 87%
F-Score 3 5 19%

Lifecore Biomedical, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors